Roche dumps lead asset from its $725M Seragon buy

ARN-810 was leading the pack in Roche's acquired portfolio of investigational next-generation oral SERDs.

Back in 2014, Roche spent $725 million upfront on Seragon Pharmaceuticals, but three years down the line, it has now canned work on its leading drug, ARN-810.

In its first-quarter results announced today, the Swiss major quietly announced that the next-gen SERD drug, RG6046, has been “removed from phase 2” in HER negative advanced breast cancer.

No other details were given, but the compound appears to have been removed from the company’s roster of pipeline meds.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

RELATED: Special Report: Roche tops big pharma's top R&D spenders for 2016 

Roche paid $725 million (with $1 billion in biobucks) for Seragon, a privately held biotech based in San Diego, California, three years ago.

Roche got access to Seragon's entire portfolio of investigational next-generation oral selective estrogen receptor degraders (SERDs) for the potential treatment of hormone receptor-positive breast cancer. ARN-810 had been leading that pack, and was in phase 1 when it was subsumed into Roche.

Other meds from its buyout are still lined up in its pipeline, however, including RG6047 (GDC-0927, or ARN-927). 

Suggested Articles

By employing heart rate signals, physical activity and sleep quality, common Fitbit trackers may be able to predict the spread of the flu.

Nanox has raised $26 million to help fuel the development and commercialization of its "Star Trek"-inspired digital X-ray bed.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.